SAB Biotherapeutics, Inc.
SABSNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $226.50M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.44$5.15
- Volume (live)
- -
- Avg. volume (3M)
- 737.14K
SAB Biotherapeutics (SABS) Stock Price & Financial Analysis
SAB Biotherapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.82 - $3.04 |
|---|---|
| 52-Week High | $5.15 |
| 52-Week Low | $2.44 |
| Open | $2.98 |
| Volume (last close) | 1.02M |
| Average Volume (3M) | 737.14K |
| 50-Day MA | $3.37 |
|---|---|
| 200-Day MA | $3.71 |
| 1-Year Change | +4.11% |
| Market Cap | 226.50M |
|---|---|
| Shares Outstanding | 79.75M |
| Price to Book (P/B) | 1.05 |
| EV/EBITDA | -3.54 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
SAB Biotherapeutics at a Glance
As of the Oct 23, 2026 close, SAB Biotherapeutics (SABS) has a market capitalization of $226.50M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $8.27M in cash and securities against $5.13M of debt, a net cash position of $3.13M.
SAB Biotherapeutics does not currently pay a dividend.
The share price is up 4.1% over the past year. At $2.84 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $2.44 to $5.15, below its 200-day moving average of $3.71.
Based on 3 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $12.67, 346.1% above the Oct 23, 2026 close.
Frequently Asked Questions About SAB Biotherapeutics
What is the current stock price for SABS?
As of the Oct 23, 2026 close, SABS stock trades at $2.84. The 52-week range is $2.44–$5.15, with a day range of $2.82–$3.04.
What is the P/E ratio for SABS?
The P/E ratio (Price-to-Earnings) for SABS is shown in the Key Statistics section. This valuation metric helps compare SAB Biotherapeutics, Inc. to industry peers.
Does SABS pay dividends?
SAB Biotherapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for SABS?
Based on ratings from 3 professional analysts over the last 90 days, the consensus for SABS is Buy. The average 12-month price target is $12.67, a 346.1% upside from the Oct 23, 2026 close of $2.84.
What is the market cap of SABS?
As of the Oct 23, 2026 close, SAB Biotherapeutics's market capitalization is $226.5M, classifying it as a micro-cap company. SAB Biotherapeutics operates in the Healthcare sector within the Biotechnology industry.